Phase 3 IGIV, 10% in Alzheimer´s Disease
2021年4月30日 更新者：Baxalta now part of Shire
A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease
The purpose of this study is to provide evidence of efficacy and safety to support the development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s Disease.
調査の概要
状態
終了しました
条件
研究の種類
介入
入学 (実際)
508
段階
- フェーズ 3
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ
-
-
Arizona
-
Phoenix、Arizona、アメリカ
-
-
California
-
Long Beach、California、アメリカ
-
San Diego、California、アメリカ
-
Santa Ana、California、アメリカ
-
-
Florida
-
Boca Raton、Florida、アメリカ
-
Delray Beach、Florida、アメリカ
-
Edgewater、Florida、アメリカ
-
Orlando、Florida、アメリカ
-
-
Georgia
-
Decatur、Georgia、アメリカ
-
-
Illinois
-
Chicago、Illinois、アメリカ
-
Springfield、Illinois、アメリカ
-
-
Kentucky
-
Paducah、Kentucky、アメリカ
-
-
Minnesota
-
Saint Paul、Minnesota、アメリカ
-
-
Mississippi
-
Olive Branch、Mississippi、アメリカ
-
-
Nevada
-
Las Vegas、Nevada、アメリカ
-
-
New Jersey
-
Berlin、New Jersey、アメリカ
-
Chester、New Jersey、アメリカ
-
Eatontown、New Jersey、アメリカ
-
Summit、New Jersey、アメリカ
-
Toms River、New Jersey、アメリカ
-
-
New York
-
Albany、New York、アメリカ
-
Brooklyn、New York、アメリカ
-
Latham、New York、アメリカ
-
Manhasset、New York、アメリカ
-
New Hyde Park、New York、アメリカ
-
-
Ohio
-
Cincinnati、Ohio、アメリカ
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ
-
Tulsa、Oklahoma、アメリカ
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ
-
-
Texas
-
Austin、Texas、アメリカ
-
Dallas、Texas、アメリカ
-
Houston、Texas、アメリカ
-
San Antonio、Texas、アメリカ
-
-
Vermont
-
Bennington、Vermont、アメリカ
-
-
Virginia
-
Charlottesville、Virginia、アメリカ
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ
-
-
-
-
-
Bath、イギリス
-
Brentford、イギリス
-
Brighton、イギリス
-
Glasgow、イギリス
-
-
East Sussex
-
Uckfield、East Sussex、イギリス
-
-
-
-
South Australia
-
Woodville South、South Australia、オーストラリア
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ
-
-
Quebec
-
Greenfield Park、Quebec、カナダ
-
Sherbrooke、Quebec、カナダ
-
-
-
-
-
Barcelona、スペイン
-
Madrid、スペイン
-
Valencia、スペイン
-
-
Vizcaya
-
Barakaldo、Vizcaya、スペイン
-
-
-
-
-
Edegem、ベルギー
-
Gent、ベルギー
-
Hasselt、ベルギー
-
Leuven、ベルギー
-
Roeselare、ベルギー
-
-
-
-
-
Lublin、ポーランド
-
Scinawa、ポーランド
-
Warszawa、ポーランド
-
-
-
-
-
Akashi、日本
-
Akita、日本
-
Azumino、日本
-
Chiba、日本
-
Fukui、日本
-
Kyoto、日本
-
Niigata、日本
-
Osaka、日本
-
Saga、日本
-
Tokushima、日本
-
Tokyo、日本
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
50年～89年 (大人、高齢者)
健康ボランティアの受け入れ
いいえ
受講資格のある性別
全て
説明
Inclusion Criteria:
- Males or females of age 50 to 89 years inclusive at the time of screening
- Written informed consent obtained from either the subject or the subject's legally authorized representative prior to any study-related procedures
- Written informed consent obtained from an able and competent caregiver who is willing to comply with the requirements of the protocol pertaining to him/her, including facilitating the subject's participation in the study
- Diagnosis of Probable Alzheimer´s Disease (AD) according to NINCDS-ADRDA* 1984 criteria (* National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association)
- Dementia of mild to moderate severity (Mini-Mental State Examination [MMSE] 16-26 inclusive at the time of screening)
- Neuroimaging (computed tomography [CT] or MRI) performed after symptom onset consistent with AD diagnosis
- Willingness to comply with the requirements of the protocol and ability to comply with testing and infusion regimen, including adequate corrected visual acuity and hearing ability
- For at least 12 weeks prior to screening, on stable doses of AD medication(s) approved by local regulatory authorities. Subjects must not be on two acetylcholinesterase inhibitors concurrently.
- Venous access for repeated infusion and phlebotomy
- If receiving psychoactive medications (eg, antidepressants other than monoamine oxidase inhibitors [MAOIs] and most tricyclics, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, etc.), must be on stable doses for at least 6 weeks prior to screening
- For women of childbearing potential, the subject must have a negative pregnancy test at screening and must agree to employ adequate contraceptive measures (eg, birth control pills/patches, intrauterine device, or diaphragm or condom [for male partner] with spermicidal jelly or foam) throughout the course of the study
- For subjects with a coronary artery stent, the subject must receive documented medical clearance from an interventional cardiologist stating that the subject is not at increased risk for stent occlusion with immunoglobulin treatment
- For subjects with an endovascular stent, the subject must receive documented medical clearance from a vascular surgeon stating that the subject is not at increased risk for thromboembolic events with immunoglobulin treatment
Main Exclusion Criteria:
- Possible AD by NINCDS-ADRDA criteria or non-Alzheimer dementia (eg, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, or dementia arising from other diseases or conditions such as Parkinson's disease, vitamin B12 deficiency, thyroid abnormalities)
- Current residence in a skilled nursing facility
- Contraindication to undergoing MRI (eg, pacemaker [with the exception of an MRI-compatible pacemaker], severe claustrophobia, ferromagnetic implants such as a metal plate)
- Clinically significant congestive heart failure (eg, New York Heart Association [NYHA] Class III/IV symptoms or untreated Class II)
- Current atrial fibrillation of unstable angina (angina at rest) or history of myocardial infarction within the 12 months prior to screening
- Uncontrolled hypertension defined as systolic blood pressure > 160 mm Hg and/or diastolic > 100 mm Hg confirmed upon repeated measures
- History of thrombosis and/or thromboembolic disease (central or peripheral) within the 12 months prior to screening
- Known history of procoagulant abnormalities (eg, factor V Leiden, antiphospholipid syndrome, protein S/protein C deficiency, AT III deficiency)
- History of intracerebral hemorrhage within the 5 years prior to screening
- Evidence on MRI of: greater than 4 microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"), a single area of superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, prominent white matter disease with a rating score of 3 on the age-related white matter changes (ARWMC) scale from the European Task Force on ARWMC, or multiple lacunae (defined as more than 2 lacunae that are greater than 0.5 mm in size)
- Head trauma with loss of consciousness, contusion, or open head injury within the 12 months prior to screening
- Uncontrolled seizure disorder as defined by two or more breakthrough seizures per year despite adequate antiepileptic drug (AED) treatment
- Modified Hachinski score > 4 at time of screening
- Subjects with active malignancy or history of malignancy within 5 years prior to screening with the exception of the following: adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable prostate cancer not requiring treatment
- Active autoimmune or neuro-immunologic disorder
- Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)
- Poorly controlled diabetes, defined as glycosylated (or glycated) hemoglobin (HbA1c) ≥ 6.5% at screening
- Creatinine clearance < 50% of normal adjusted for age and gender, as calculated according to the Cockcroft-Gault formula, at the time of screening
- Known history of untreated vitamin B12 deficiency within 6 months prior to screening, or clinically significant abnormally low vitamin B12 at the time of screening
- Abnormal clinical chemistry panel or hematology panel meeting any one of the following criteria:
- Serum alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
- Clinically significant anemia that precludes repeated blood sampling or hemoglobin (Hgb) < 10.0 g/dL
- Absolute neutrophil count (ANC) < 1000 cells/µL
- Known coagulopathy or platelet counts < 100,000 cells/µL
- Total serum protein > 9 g/dL
- Known history of or positive serology at screening for one or more of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) type 1/2 antibody
- Immunoglobulin A (IgA) deficiency (< 8 mg/dL)
- Known history of hypersensitivity following infusions of human blood or blood components (e.g. human immunoglobulins or human albumin)
- Currently receiving or has received: anti-CD20 therapy within 12 months prior to screening, or other immunomodulatory therapies (e.g. anti-TNF, anti-IL-1, interferon) within 12 weeks prior to screening. The following exceptions are allowed: non-systemic corticosteroids (eg, topical, opthalmic or inhaled glucocorticoids) and low-dose systemic corticosteroids (prednisone < 10 mg/day or its equivalent)
- Currently receiving or has received intravenous or subcutaneous immunoglobulin treatment within the 2 years prior to screening, or has received immunoglobulin in Baxter Protocol 160701
- Currently receiving or has received at any time active immunization aimed at modulating AD progression
- Currently receiving or has received within 12 months prior to screening any investigational device, drug or biologic (eg passive immunotherapies with monoclonal or polyclonal antibodies) aimed at modulating AD progression
- Subject has been exposed to an investigational product (IP) or investigational device within 12 weeks prior to screening or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study
- Subject is a family member or employee of the investigator
- The subject is nursing or intends to begin nursing during the course of the study
- Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, urine tests, electrocardiogram, chest x-ray), that in medical judgment may impede the subject's participation in the study, pose increased risk to the subject, or confound the results of the study
- Currently receiving anti-coagulant agent and/or anti-platelet agent other than acetylsalicylic acid (a.k.a. aspirin)
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター：プラセボ対照
|
Intravenous infusion every 2 weeks over 18 months
|
|
実験的：IGIV, 10% at high dose (0.4 g/kg)
|
Intravenous infusion every 2 weeks over 18 months
他の名前：
|
|
実験的：IGIV, 10% at low dose (0.2 g/kg)
|
Intravenous infusion every 2 weeks over 18 months
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)
時間枠：Baseline to 9 Months (actual time frame)
|
The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs).
This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.
|
Baseline to 9 Months (actual time frame)
|
|
Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory
時間枠：Baseline to 9 Months (actual time frame)
|
The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.
|
Baseline to 9 Months (actual time frame)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ADCS-Clinical Global Impression of Change (CGIC) at 18 Months
時間枠：Baseline to 9 Months (actual time frame)
|
The ADCS-CGIC is a validated categorical measure of change in a participant's global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment.
The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).
|
Baseline to 9 Months (actual time frame)
|
|
Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)
時間枠：Baseline to 9 Months (actual time frame)
|
The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change.
The NPI total score ranged 0-144, with higher scores indicating greater impairment.
|
Baseline to 9 Months (actual time frame)
|
|
Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement
時間枠：Baseline to 9 Months (actual time frame)
|
Baseline to 9 Months (actual time frame)
|
|
|
Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)
時間枠：Baseline to 9 Months (actual time frame)
|
The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia.
The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains.
The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.
|
Baseline to 9 Months (actual time frame)
|
|
Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)
時間枠：Baseline to 9 Months (actual time frame)
|
The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers.
Higher scores on the IADCQ are associated with a higher impact.
IADCQ total score range: 0 (no impact) - 48 (greatest impact).
Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely).
As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.
|
Baseline to 9 Months (actual time frame)
|
|
Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
時間枠：Throughout the study period: 18 Months
|
Throughout the study period: 18 Months
|
|
|
Number of Participants Experiencing Any AEs and/or SAEs
時間枠：Throughout the study period: 18 Months
|
Throughout the study period: 18 Months
|
|
|
Number of Infusions Temporally Associated With AEs and/or SAEs
時間枠：During or within 72 hours of completion of an infusion
|
A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.
|
During or within 72 hours of completion of an infusion
|
|
Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion
時間枠：During or within 7 days of completion of an infusion
|
During or within 7 days of completion of an infusion
|
|
|
Number of Infusions Causally Associated With AEs and/or SAEs
時間枠：Throughout the study period: 18 Months
|
Throughout the study period: 18 Months
|
|
|
Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE
時間枠：Throughout infusions, approximately 2-5 hours
|
Throughout infusions, approximately 2-5 hours
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2012年1月23日
一次修了 (実際)
2013年7月16日
研究の完了 (実際)
2013年7月16日
試験登録日
最初に提出
2012年1月20日
QC基準を満たした最初の提出物
2012年1月31日
最初の投稿 (見積もり)
2012年2月2日
学習記録の更新
投稿された最後の更新 (実際)
2021年5月19日
QC基準を満たした最後の更新が送信されました
2021年4月30日
最終確認日
2021年4月1日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。